Publications

Validation of microRNA pathway polymorphisms in esophageal adenocarcinoma survival.
Cancer Med 2017 Feb 11;6(2):361-373. Epub 2017 Jan 11.
Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.


A Bridging Opportunities Work-frame to develop mobile applications for clinical decision making.
Future Sci OA 2015 Nov 1;1(3):FSO8. Epub 2015 Nov 1.
Faculty of Pharmacy & Pharmaceutical Sciences, 3142, Katz Group Centre for Pharmacy & Health Research, University of Alberta, Edmonton, Alberta, AB T6G 2E1, Canada; Faculty of Pharmacy & Pharmaceutical Sciences, 3142, Katz Group Centre for Pharmacy & Health Research, University of Alberta, Edmonton, Alberta, AB T6G 2E1, Canada.

Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Carcinogenesis 2015 Sep 25;36(9):956-62. Epub 2015 May 25.
Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, 610 University Ave, Toronto, Ontario M5G 2M9, Canada.


The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.
Oncol Rep 2011 Jun 6;25(6):1765-72. Epub 2011 Apr 6.
School of Pharmacy, University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin, Madison, WI 53792-5669, USA.


Interaction between PPARA genotype and beta-blocker treatment influences clinical outcomes following acute coronary syndromes.
Pharmacogenomics 2008 Oct;9(10):1403-17
Department of Medicine, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8086, Saint Louis, MO 63110-1093, USA.



A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
J Thorac Oncol 2006 Nov;1(9):972-8
Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.


Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Invest New Drugs 2006 Sep;24(5):393-401
Hillman Cancer Research Center, Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

OF